BiconY Therapeutics – beating cancer
BiconY Therapeutics: bispecific antibodies in the fight against cancer
Mixed doubles: the “2 targets – 2 signals” approach to cancer
Cancer as a widespread disease:
The opening serve for a better world
Cancer has become a widespread disease all over the world and is one of the biggest challenges to global health. The prevalence of cancer diseases has been rising constantly in recent years, and the number of new cases is forecast to increase further in the coming decades, with a 23% increase forecast by 2030.
This alarming figure emphasises the urgency of developing innovative approaches in cancer research and treatment. Not only does cancer affect individual patients; it also has significant impacts on the healthcare system and society as a whole. It is crucial to raise awareness, fund research and drive therapeutic progress in order to combat this challenge effectively. Now, BiconY Therapeutics is sending out an unbeatable pair in the match against cancer!
Bispecific antibodies in cancer immunotherapy are designed to activate the immune system against cancer in a targeted way. By simultaneously binding to T cells and cancer cells, they promote a precision immune response by stimulating T cells to target and destroy cancer cells. This innovative approach promises a more effective but also gentler and more targeted treatment for cancer. BiconY is launching the latest Open in the fight against cancer!
SPRIND: who is behind BiconY Therapeutics?
BiconY GmbH: a force for innovation in cancer research
BiconY GmbH, based in Leipzig, is a limited liability pharmaceutical company that specialises in the preclinical and clinical research and development of pharmaceutical substances to treat oncological diseases, primarily solid tumours. The company follows a clear corporate purpose that covers all the associated actions, research findings and transfer of knowledge. In line with the principles of sustainability, BiconY strives to develop groundbreaking therapeutic approaches that are not only effective but also viable in the long term.
Government support for the future of cancer treatment:
BiconY GmbH is backed by the Federal Republic of Germany in the form of the Federal Agency for Disruptive Innovation (SPRIND), which is providing the company with significant financing of 45 million euros over several years. This substantial financial contribution underscores the Federal Government’s commitment to innovative research and development in the field of cancer therapy. The funding enables BiconY to drive pioneering research projects, investigate new therapeutic approaches and, ultimately, make a significant contribution to the fight against cancer. Through this partnership, BiconY Therapeutics GmbH endeavours to play a substantial part in shaping the future of cancer treatment with sophisticated medical solutions!
Our partners and supporters:
In cooperation with:
Funded by:
What approach is BiconY Therapeutics following in tumour therapy?
Radiotherapy and chemotherapy are sufficiently familiar treatments for tumours and remain the standard for treating cancer patients. However, both of these types of treatment not only attack the tumour cells, but also place an enormous strain on healthy areas of the body.
For that reason, research is looking into alternative, gentler treatment methods. BiconY has dedicated itself to the research area of bispecific antibodies.
What are bispecific antibodies?
Bispecific antibodies are proteins that have been specially developed to identify and bind to two different targets simultaneously. In the context of cancer immunotherapy, bispecific antibodies have the potential to mobilise the immune system to target cancer cells. BiconY’s therapeutic approach works by combining two signals.
The bispecific CD3 antibodies activate the T cells, thereby supplying the first signal, and the second signal is provided by the bispecific costimulators. In brief, a strong forehand is good, but combining it with a strong backhand is even better!
Here are some of the basic properties of bispecific antibodies:
- Targeted binding: Bispecific antibodies can bind to two different target structures. This enables them to bind to cancer cells as well as immune cells.
- Immune activation: By binding to cancer cells and immune cells, bispecific antibodies bring them close together. This promotes the targeted activation of the immune system against the cancer cells.
- T cell recruitment: A common design of bispecific antibodies is aimed at recruiting T cells, a key component of the immune system. This enables a stronger immune response to cancer cells.
- Tumour destruction: The recruited T cells can then exert their cytotoxic effect on the cancer cells, which leads to the targeted destruction of those cells.
- Flexibility of design: There are various designs for bispecific antibodies depending on the specific requirements of the therapy. Some may be aimed at recruiting different subtypes of T cells, while others are designed to identify specific tumour antigens.
Bispecific antibodies are a promising approach to immunotherapy and are at various different stages of clinical development for different types of cancer. Their potential lies in their ability to use the immune system in a targeted way and cause precise anti-tumour activity. Compared to chemotherapy, this type of treatment places less strain on patients and its side effects are much smaller in scale. As well as this, our technology has the potential to provide a sustained immune response to tumour cells. At BiconY, we hope one day to be able to declare: “Game, set and match!”
Frequently asked questions
Answers to your most important questions about BiconY Therapeutics GmbH
What goals does BiconY Therapeutics GmbH pursue?
The stated objective of BiconY Therapeutics is the effective combating of different cancers. Our focus in this area is on the research and development of what are known as bispecific antibodies.
How was BiconY Therapeutics formed?
The Limited Company was founded by order of the Federal Agency for Leap Innovations, or SPRIND for short. SPRIND is a flexible instrument for government funding, under the supervision of the Federal Ministry of Education and Research (BMBF) and the Federal Ministry for Economic Affairs and Climate Action (BMWK). Its purpose is the identification, development, support and acceleration of innovative ideas. This is aimed at improving Germany’s competitiveness as a business centre as well as maintaining and creating prosperity and jobs.
Does BiconY offer good employment opportunities?
Yes, in fact as a biotech start-up we are always looking for motivated people to enrich our company. We need creative minds, prodigies, pioneers, doers, enthusiasts, adventurers, courageous and decisive people – in short, heroes!
How is BiconY Therapeutics GmbH financed?
We are publicly funded, but it is also possible to support our research financially. For more information please contact TWYCE GmbH, which is founded by Prof. Gundram Jung, Dr. Martin Pflügler and Prof. Helmut Salih and of course has access to all our research findings.
You are leaving our website
You are leaving our website and we cannot be held responsible for the content of external websites.
You are leaving our website
You are leaving our website and we cannot be held responsible for the content of external websites.
You are leaving our website
You are leaving our website and we cannot be held responsible for the content of external websites.
